{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:41:51Z","timestamp":1792759311787,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clindermatol.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:42:35Z","timestamp":1791330155000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The ethical and practical issues of market exclusivity for naturally derived dermatologic medications: The case of cantharidin"],"prefix":"10.1016","author":[{"given":"Danielle M.","family":"Khalilzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Klufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert E.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.10.001_bib0001","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archderm.137.10.1357","article-title":"Cantharidin revisited: a blistering defense of an ancient medicine","volume":"137","author":"Moed","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaad.2022.07.020","article-title":"Ethical issues of compounding cantharidin in dermatology","volume":"89","author":"Fabbro","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40272-023-00600-y","article-title":"Cantharidin topical solution 0.7%: first approval","volume":"26","author":"Keam","year":"2024","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0004","series-title":"Compounded drug products that are essentially copies of a commercially available drug product under section 503\u202fA of the Federal Food, Drug, and Cosmetic Act: guidance for industry","year":"2018"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2022.02.048","article-title":"The vexing voyage of vasopressin","volume":"162","author":"Bendicksen","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0006","unstructured":"US Food and Drug Administration. Frequently asked questions on patents and exclusivity. Available at: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity. Accessed September 30, 2026."},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0007","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMp1003126","article-title":"Incentives for drug development \u2013 the curious case of colchicine","volume":"362","author":"Kesselheim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0008","first-page":"177","article-title":"ASHP-PPAG guidelines for providing pediatric pharmacy services in hospitals and health systems","volume":"23","author":"Eiland","year":"2018","journal-title":"J Pediatr Pharmacol Ther."},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0009","article-title":"In brief: mechlorethamine gel (Valchlor) for cutaneous T-cell lymphoma","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.clindermatol.2026.10.001_sbref0010","series-title":"UMP pharmacy preauthorization criteria \u2013 part 2","year":"2026"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0012","series-title":"Compounded drugs: payment practices vary across public programs and private insurers, and Medicare Part B policy should be clarified","year":"2014"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0013","unstructured":"Centers for Medicare & Medicaid Services. Early and periodic screening, diagnostic, and treatment. Available at: https:\/\/www.medicaid.gov\/medicaid\/benefits\/early-and-periodic-screening-diagnostic-and-treatment. Accessed September 30, 2026."},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2026.10.001_bib0014","first-page":"S12","article-title":"Comprehensive management of molluscum contagiosum: assessment of clinical associations, comorbidities, and management principles","volume":"16","author":"Bhatia","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2026.10.001_bib0015","first-page":"647","article-title":"Cutaneous warts: an evidence-based approach to therapy","volume":"72","author":"Bacelieri","year":"2005","journal-title":"Am Fam Physician"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:54:54Z","timestamp":1792756494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S0738081X26002956"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.10.001","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ethical and practical issues of market exclusivity for naturally derived dermatologic medications: The case of cantharidin","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}